CLICKMER
LIVE

Serial Number

97677631

Owner

Clickmer Systems GmbH

Attorney

LEIGH ANN LINDQUIST

Filing Date

Nov 15, 2022

Add to watchlist:

No watchlists yet
View on USPTO

CLICKMER Trademark

Serial Number: 97677631 • Registration: 7459774

CLICKMER is a trademark filed by Clickmer Systems GmbH on November 15, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Clickmer Systems GmbH

Marie-Curie-Straße 1
Rheinbach 53359 , DE

Entity Type: 16

Trademark Details

Filing Date

November 15, 2022

Registration Date

July 30, 2024

Published for Opposition

May 14, 2024

Goods & Services

Chemical, biological, biochemical, biotechnological and pharmaceutical products and preparations, namely, DNA/RNA oligonucleotides, antibodies, nucleic acids, proteins, lipids, polysaccharides, enzymes, peptides, microorganisms, cell cultures and cells as well as fragments, fractions and derivatives thereof, for medical, veterinary or pharmaceutical purposes, namely, for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination and immunostimmulation; therapeutic agents for medical, veterinary and pharmaceutical purposes, namely, for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination and immunostimmulation, medicaldiagnostic agents for medical, veterinary and pharmaceutical purposes; preparations for health care, namely, medicinal preparations for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination and immunostimmulation; Medicines for for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination and immunostimmulation, vaccines

Chemical preparations, biological preparations and biochemical preparations for industrial and scientific use; Biotechnological preparations, namely, cells, proteins, enzymes, peptides, cultures of microorganisms for industrial and scientific use; Chemical preparations, biological preparations, biochemical preparations and biotechnological preparations, namely, diagnostic preparations other than for medical or veterinary purposes; Chemical additives for use in the manufacture of pharmaceuticals; Chemical, biological, biochemical and biotechnological products and preparations for use in the manufacturing of pharmaceuticals, namely, DNA/RNA oligonucleotides, antibodies, nucleic acids, proteins, lipids, polysaccharides, enzymes, peptides, microorganisms, cell cultures and cells as well as fragments, fractions and derivatives thereof

Medical and veterinary services; medical and veterinary diagnostic services, namely, laboratory services for diagnosis of diseases and genetic defects

Scientific research and development for third parties, especially in the fields of diagnostics, pharmaceuticals, chemistry, biology, biochemistry and biotechnology; scientific and technological services, namely, providing medical research information and scientific research information, feasibility studies, testing services and analysis services in the fields of diagnostics, pharmaceuticals, chemistry, biology, biochemistry and biotechnology; scientific laboratory and chemical, biological, biochemical, biotechnological and pharmaceutical analytical services

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 15, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Aug 15, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 15, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 15, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 15, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 15, 2024 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 30, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 30, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 14, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 14, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 24, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 8, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 13, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 13, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 12, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Dec 13, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Dec 13, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 15, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 15, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 15, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 29, 2023 DOCK
ASSIGNED TO EXAMINER
Aug 29, 2023 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jan 23, 2023 AMPX
ASSIGNED TO LIE
Jan 23, 2023 ALIE
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 6, 2022 NWOS
TEAS VOLUNTARY AMENDMENT RECEIVED
Nov 22, 2022 PARI
NEW APPLICATION ENTERED
Nov 18, 2022 NWAP